Member Info for beinthelead

Spot on, once again Apre.

Ah, Joe. Nice to meet you. You must be new? Binned.

The account has conned the board for a few months. It’s that lunatic.

RAH’s logic is sound.

Safety was proven last December. They’ve analysed data to verify that proof for the past 9-10 months.

Efficacy has likely lagged the safety data for some months, but I believe they’ll have some data to underpin MoA and P1b strategy.

Refreshing having that repetitive lunatic on block. It’s got to be Ndn. That said, at least he got the message…

Brontë - nice. See if they can escape.

Bang on Xnoz. And Mr A. That troll is hopefully eradicated.

Great result today. I get more impressed with the way they’re conducting their business. Let’s go.

I’m on the fence. If the RNS says do it, I’m in. Otherwise I’ll wait for news.

Arrrgghhh! 25p and a ring pop.

Ramper. 20p for the lot.

RNSs. What a superstar. Where are the commercial deals from the LFT?? Ink pot dry? Absolute rubbish.

You are a troll. Binned.

If you say so!!!!!!!!!!!!!!

Literally start an argument in an empty room. You’ve spoiled more debates than you’ve contributed to.

Is it Wyn? Seriously.

You can’t stop it. It’s a p1ss take account.

I’m betting on cohort 26 to run for 9 weeks exactly. You heard it here first.

You mean, the other 986 companies presenting on FAP have been waiting for Avacta data??

Reminds me of the wait for LFT CE Mark. This is literally a clinical trial with non binary outcomes. It comes when it comes.

Ahhh!! But… what about the brochure?? ‘Key’?

‘No new information’, really means…

Yes, that’s a good read JRDC.

Efficacious doses above 225mg? Doesn’t pass the giggle test. Or P1 in this instance.

Here you go Rip;

“An ideal drug candidate would have high potency and specificity to inhibit its molecular target without off-target effect, high drug exposure in disease-targeted tissues to achieve adequate efficacy at an optimal dose (ideally at low doses), and minimal drug exposure in healthy tissues to avoid toxicity at optimal doses (even at high doses)”

Whilst we’re on effective dosing. How much of the dox is being ‘used’? Bang-for-buck type measure.

L-377202 was ineffective at doses below 225mg. Think about that.

On TMAC again; this trial is finding the key to the lock. Find the key, the safe holds 20x the value of AVA6000.

Yes, quite.

Trouble being the river may be narrow, then widen, then narrow again. :).

It’s academic anyway. If we can defeat the stroma and drop the dox bomb in there, continually, it accumulates, we’ve achieved something others have dreamt about. Whilst minimising AEs, of course.

We should achieve effective excellent outcomes in P2/3. Other drugs have sailed through P2 with relatively poor performance at P1.